Tag: press

DALLAS, TX, June 03, 2026 (GLOBE NEWSWIRE) -- Long Table Growth Corp. (the “Company”) today announced the pricing of its initial public offering of 15,000,000 units at a price of $10.00 per unit. The units are expected to commence trading on The Nasdaq Global Market (“Nasdaq”) under the ticker symbol “LTGRU” beginning on June 4, 2026. Each unit sold in the offering consists of one Class A ordinary share and one-half of one redeemable warrant, with each whole warrant exercisable to purchase one Class A ordinary share at a price of $11.50 per share, subject to certain adjustments. Only whole warrants will be exercisable. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols “LTGR” and “LTGRW,” respectively. The offering is expected to close on June 5, 2026, subject to customary closing conditions.

Reinforces Seer’s Clear Strategy, Strong Governance and Significant Long-Term Value Creation Opportunity

ARLINGTON, TX, June 03, 2026 (GLOBE NEWSWIRE) -- Greenway Technologies, Inc. (OTCQB: GWTI) (“Greenway”), an advanced gas-to-liquids (“GTL”) and gas-to-hydrogen (“GTH”) technology development company, announced that on May 28, 2026, Raymond Wright notified the Board of Directors (the “Board”) of Greenway of his resignation from his positions as a Board member and as Interim President of Greenway, effective on such date. In connection with his transition, the Board unanimously approved the conferral of the honorary title Chairman Emeritus in recognition of Mr. Wright’s long-standing leadership and foundational contributions to Greenway. The role of Chairman Emeritus is not a Board position and does not carry a vote.

SINGAPORE, June 03, 2026 (GLOBE NEWSWIRE) -- Phaos Technology Holdings (Cayman) Limited, (NYSE: POAS), (“the Company”), an advanced microscopy solutions headquartered in Singapore, announced today that the Company had become aware of unusual trading activity in its class A ordinary shares on the New York Stock Exchange American (the "NYSE") from May 29, 2026 to June 1, 2026. The Company is issuing this updated press release pursuant to Section 401(d) of the NYSE Company Guide. The Company has made inquiries and has been unable to determine whether corrective actions are appropriate at this time. The Company is further announcing that there has been no material development in its business and affairs not previously disclosed or, to its knowledge, any other reason to account for the unusual market action.

CALGARY, Alberta, June 03, 2026 (GLOBE NEWSWIRE) -- PHX Energy" or the "Corporation") (TSX: PHX) announces that its Board of Directors (the "Board") has approved an increase to its 2026 capital expenditure program (the "Program") to $80 million, a $15 million increase from the previously announced Program.

New York, NY, June 03, 2026 (GLOBE NEWSWIRE) -- Bayview Acquisition Corp (NASDAQ: BAYA, BAYAU, and BAYAR) (the “Company”) announced that, at its extraordinary general meeting of shareholders held on May 28, 2026 (the “Meeting”), its shareholders approved the proposals to extend the deadline by which the Company must complete its initial business combination, and that redemptions in connection with the vote were limited.

New York, June 03, 2026 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of a registered direct offering (the “Offering”) of approximately $8 million for its client Hitek Global Inc. (NASDAQ: HKIT) (the “Company”), a China-based information technology consulting and solutions service provider.

Langenfeld, Germany, June 03, 2026 (GLOBE NEWSWIRE) -- Booking Health today announced the release of findings examining international patient access to personalized dendritic cell therapy for glioblastoma in Germany. The findings, based on a documented Canadian patient case and supporting clinical research, highlight how cross-border treatment pathways may provide patients with aggressive brain tumors access to individualized immunotherapy options that are not widely available within all healthcare systems.